Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency
Journal of Clinical Immunology · 2024
DOI: 10.1007/s10875-024-01710-z ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Clinical Immunology, 2024. Verfasst von Elizabeth Daly Hicks und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Transplant and Cellular Therapies, Duke University Medical Center, Durham, NC, USA. Hauptthemen laut MEDLINE: Adenosine Deaminase, Agammaglobulinemia, Enzyme Replacement Therapy, Severe Combined Immunodeficiency. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH T32 Training Grant, The Jeffrey Modell Foundation.
Abstract (Originalsprache)
Purpose
Patients with adenosine deaminase 1 deficient severe combined immunodeficiency (ADA-SCID) are initially treated with enzyme replacement therapy (ERT) with polyethylene glycol-modified (PEGylated) ADA while awaiting definitive treatment with hematopoietic stem cell transplant (HSCT) or gene therapy. Beginning in 1990, ERT was performed with PEGylated bovine intestinal ADA (ADAGEN®). In 2019, a PEGylated recombinant bovine ADA (Revcovi®) replaced ADAGEN following studies in older patients previously treated with ADAGEN for many years. There are limited longitudinal data on ERT-naïve newborns treated with Revcovi.
Methods
We report our clinical experience with Revcovi as initial bridge therapy in three newly diagnosed infants with ADA-SCID, along with comprehensive biochemical and immunologic data.
Results
Revcovi was initiated at twice weekly dosing (0.2 mg/kg intramuscularly), and monitored by following plasma ADA activity and the concentration of total deoxyadenosine nucleotides (dAXP) in erythrocytes. All patients rapidly achieved a biochemically effective level of plasma ADA activity, and red cell dAXP were eliminated within 2–3 months. Two patients reconstituted B-cells and NK-cells within the first month of ERT, followed by naive T-cells one month later. The third patient reconstituted all lymphocyte subsets within the first month of ERT. One patient experienced declining lymphocyte counts with improvement following Revcovi dose escalation. Two patients developed early, self-resolving thrombocytosis, but no thromboembolic events occurred.
Conclusion
Revcovi was safe and effective as initial therapy to restore immune function in these newly diagnosed infants with ADA-SCID, however, time course and degree of reconstitution varied. Revcovi dose may need to be optimized based on immune reconstitution, clinical status, and biochemical data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Pediatric Transplant and Cellular Therapies, Duke University Medical Center, Durham, NC, USA.
- Department of Pediatrics, Division of Pediatric Allergy and Immunology, Duke University Medical Center, Durham, NC, USA.
- Department of Medicine, Division of Rheumatology and Immunology, Duke University School of Medicine, Durham, NC, USA.
- Department of Biochemistry, Duke University School of Medicine, Durham, NC, USA.
- Department of Medicine, Division of Rheumatology, Durham Veteran Affairs Medical Center, Durham, NC, USA.
- Department of Pediatrics, Division of Allergy and Immunology, Duke University School of Medicine, Durham, NC, USA.
ORCID-Profile: Elizabeth Daly Hicks, Geoffrey Hall, Michael S Hershfield, Teresa K Tarrant, John W Sleasman, Rebecca H Buckley, Talal Mousallem
Förderung
- NIAID NIH HHS
- NIH T32 Training Grant
- The Jeffrey Modell Foundation
Zitieren
APA
Hicks, E. D., Hall, G., Hershfield, M. S., Tarrant, T. K., Bali, P., Sleasman, J. W., Buckley, R. H., & Mousallem, T. (2024). Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-024-01710-z
Vancouver
Hicks ED, Hall G, Hershfield MS, Tarrant TK, Bali P, Sleasman JW, et al. Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency. Journal of Clinical Immunology. 2024. doi:10.1007/s10875-024-01710-z
BibTeX
@article{Hicks2024,
author = {Hicks, Elizabeth Daly and Hall, Geoffrey and Hershfield, Michael S and Tarrant, Teresa K and Bali, Pawan and Sleasman, John W and Buckley, Rebecca H and Mousallem, Talal},
title = {Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency},
journal = {Journal of Clinical Immunology},
year = {2024},
doi = {10.1007/s10875-024-01710-z}
}
EUVIMED